Evidence map›Paper›PMID 32556220›Full record

ArticleNeuro-oncology2020

Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".

Olaf van Tellingen, Mark C de Gooijer, Jann N Sarkaria, William F Elmquist

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Olaf van TellingenDivision of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Mark C de GooijerDivision of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jann N SarkariaRadiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
William F ElmquistBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
The Netherlands Cancer Institute · NLMayo Clinic · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GliomaChildHumansMechanistic Target of Rapamycin Complex 1Protein Kinase InhibitorsMechanistic Target of Rapamycin Complex 1Protein Kinase Inhibitors

Identifiers

PMID32556220
PMCPMC7523448
OpenAlexW3036644052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.